414 related articles for article (PubMed ID: 33344042)
1. MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma.
de Azevedo RA; Shoshan E; Whang S; Markel G; Jaiswal AR; Liu A; Curran MA; Travassos LR; Bar-Eli M
Oncoimmunology; 2020 Dec; 9(1):1846915. PubMed ID: 33344042
[TBL] [Abstract][Full Text] [Related]
2. Blockade of MIF-CD74 Signalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response Against Metastatic Melanoma.
Figueiredo CR; Azevedo RA; Mousdell S; Resende-Lara PT; Ireland L; Santos A; Girola N; Cunha RLOR; Schmid MC; Polonelli L; Travassos LR; Mielgo A
Front Immunol; 2018; 9():1132. PubMed ID: 29875777
[TBL] [Abstract][Full Text] [Related]
3. Macrophage migration inhibitory factor-CD74 interaction regulates the expression of programmed cell death ligand 1 in melanoma cells.
Imaoka M; Tanese K; Masugi Y; Hayashi M; Sakamoto M
Cancer Sci; 2019 Jul; 110(7):2273-2283. PubMed ID: 31069878
[TBL] [Abstract][Full Text] [Related]
4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
5. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
[TBL] [Abstract][Full Text] [Related]
6. IL-32γ potentiates tumor immunity in melanoma.
Gruber T; Kremenovic M; Sadozai H; Rombini N; Baeriswyl L; Maibach F; Modlin RL; Gilliet M; von Werdt D; Hunger RE; Seyed Jafari SM; Parisi G; Abril-Rodriguez G; Ribas A; Schenk M
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32841222
[TBL] [Abstract][Full Text] [Related]
7. Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ.
Tanese K; Hashimoto Y; Berkova Z; Wang Y; Samaniego F; Lee JE; Ekmekcioglu S; Grimm EA
J Invest Dermatol; 2015 Nov; 135(11):2775-2784. PubMed ID: 26039541
[TBL] [Abstract][Full Text] [Related]
8. MIF and CD74 as Emerging Biomarkers for Immune Checkpoint Blockade Therapy.
Fey RM; Nichols RA; Tran TT; Vandenbark AA; Kulkarni RP
Cancers (Basel); 2024 May; 16(9):. PubMed ID: 38730725
[TBL] [Abstract][Full Text] [Related]
9. Recombinant
Jeong H; Lee SY; Seo H; Kim BJ
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389619
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
[TBL] [Abstract][Full Text] [Related]
11. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
12. Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion.
Yan L; Wu M; Wang T; Yuan H; Zhang X; Zhang H; Li T; Pandey V; Han X; Lobie PE; Zhu T
Cancer Res; 2024 Apr; 84(8):1270-1285. PubMed ID: 38335272
[TBL] [Abstract][Full Text] [Related]
13. PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6
De Wispelaere W; Annibali D; Tuyaerts S; Messiaen J; Antoranz A; Shankar G; Dubroja N; Herreros-Pomares A; Baiden-Amissah REM; Orban MP; Delfini M; Berardi E; Van Brussel T; Schepers R; Philips G; Boeckx B; Baietti MF; Congedo L; HoWangYin KY; Bayon E; Van Rompuy AS; Leucci E; Tabruyn SP; Bosisio F; Mazzone M; Lambrechts D; Amant F
Clin Transl Med; 2024 May; 14(5):e1655. PubMed ID: 38711203
[TBL] [Abstract][Full Text] [Related]
14. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
Kähler KC; Hassel JC; Heinzerling L; Loquai C; Thoms KM; Ugurel S; Zimmer L; Gutzmer R;
J Dtsch Dermatol Ges; 2020 Jun; 18(6):582-609. PubMed ID: 32489011
[TBL] [Abstract][Full Text] [Related]
15. Targetted inhibition of CD74 attenuates adipose COX-2-MIF-mediated M1 macrophage polarization and retards obesity-related adipose tissue inflammation and insulin resistance.
Chan PC; Wu TN; Chen YC; Lu CH; Wabitsch M; Tian YF; Hsieh PS
Clin Sci (Lond); 2018 Jul; 132(14):1581-1596. PubMed ID: 29773671
[TBL] [Abstract][Full Text] [Related]
16. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
18. Dual VEGFA/BRAF targeting boosts PD-1 blockade in melanoma through GM-CSF-mediated infiltration of M1 macrophages.
Comunanza V; Gigliotti C; Lamba S; Doronzo G; Vallariello E; Martin V; Isella C; Medico E; Bardelli A; Sangiolo D; Di Nicolantonio F; Bussolino F
Mol Oncol; 2023 Aug; 17(8):1474-1491. PubMed ID: 37183363
[TBL] [Abstract][Full Text] [Related]
19. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W
Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307
[TBL] [Abstract][Full Text] [Related]
20. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
